Manion Douglas J.
Known title: Pres and CEOCIK: 0001875875
Manion Douglas J.'s purchase track record
Manion Douglas J. has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 3/17/2023 | ACRS | $50K | +29.5% | -4.3% | +13.6% |
| 3/9/2023 | ACRS | $50K | +21.1% | -1.2% | +13.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| ACRS | ▲ Buy | Option Exercise | 27,000 | — | 1/1/2024 | View on chart |
| ACRS | ▼ Sell | Tax Withholding | 9,125 | $10K | 1/1/2024 | View on chart |
| ACRS | ▲ Buy | Option Exercise | 15,575 | — | 8/1/2023 | View on chart |
| ACRS | ▼ Sell | Tax Withholding | 4,437 | $44K | 8/1/2023 | View on chart |
| ACRS | ▲ Buy | Open Market | 6,300 | $50K | 3/17/2023 | View on chart |
| ACRS | ▲ Buy | Open Market | 6,500 | $50K | 3/9/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
ACRS Not Highlighted in Recent Pre‑Market Moves
In the past week, pre‑market activity focused on large financial names and a list of 20 stocks, but Aclaris Therapeutics was not mentioned. The moves in big banks and other sectors could influence overall market sentiment, which may affect smaller biotech names like ACRS. No direct company news was reported, so the impact is limited at this time.
ACRS Not Highlighted in Recent Pre‑Market Moves. In the past week, pre‑market activity focused on large financial names and a list of 20 stocks, but Aclaris Therapeutics was not mentioned. The moves in big banks and other sectors could influence overall market sentiment, which may affect smaller biotech names like ACRS. No direct company news was reported, so the impact is limited at this time.